OpenNashEarnings

Roche (ROG) · Pharmaceuticals

Roche H1 2026 earnings: summary, key numbers & outlook

Results filed 23 Jul 2026 · Quarter ended 30 Jun 2026

Slides (70 pages)Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Roche won five US FDA Priority Reviews and launched Axelios 1 sequencing, as divarasib beat approved KRAS G12C inhibitors in a head-to-head phase III lung cancer trial.

Roche's growth was spread across many medicines. Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo led, helped by food allergy demand, the subcutaneous Ocrevus launch and the switch from Perjeta to Phesgo. Older brands such as Avastin, Herceptin and Actemra kept shrinking under biosimilars. In Diagnostics, Pathology Lab and Core Lab grew, while China pricing reforms weighed. Roche also launched Axelios 1 and won CE marks for Elecsys pTau217 and Elecsys IGRA TB.

Management is leaning on a pipeline of up to 19 new molecular entities with launch potential by 2030, and on deals: Nurix for the bexobrutideg BTK degrader and PathAI for digital pathology. Several FDA decisions are due before year-end. The main tension is that Xolair, the top growth driver, expects its first US biosimilar in the second half of 2026, while loss of exclusivity on older brands continues.

No call transcript for this quarter, so this summary also draws on: Indian Pharma Post ↗, dpa-AFX via BÖRSE ONLINE ↗.

Slides & documents

Open the slide deck (PDF, 70 pages) ↗

Roche H1 2026 slide deck, page 1Roche H1 2026 slide deck, page 2Roche H1 2026 slide deck, page 3Roche H1 2026 slide deck, page 4Roche H1 2026 slide deck, page 5Roche H1 2026 slide deck, page 6

Showing the first 6 of 70 pages.

Results documents

Key numbers

Group sales
CHF 30.4 billion

+6% at constant exchange rates, -2% in CHF

Core operating profit · non-GAAP
CHF 11.9 billion

+10% at CER, -1% in CHF

IFRS operating profit · GAAP
CHF 9.7 billion

-6% in CHF

Core EPS, diluted · non-GAAP
10.85

+9% at CER, -2% in CHF

IFRS diluted EPS · GAAP
8.52

-8% in CHF

IFRS net income · GAAP
7.3B

-6% in CHF

Free cash flow · non-GAAP
4.2B

+26% in CHF

Operating free cash flow · non-GAAP
6.3B

+2% in CHF

Segment or metricValueChange
Pharmaceuticals Division23.6B+6% at CER, -1% in CHF
Diagnostics Division6.7B+3% at CER, -3% in CHF
Ocrevus3.5B+7% at CER
Hemlibra2.5B+11% at CER
Vabysmo2.1B+8% at CER
Xolair1.7B+27% at CER
Phesgo1.3B+18% at CER
Pathology Lab (Diagnostics)874.0M+11% at CER
Where each number comes from
  • Group sales: “In the first six months of 2026, Roche sales were +6% at CER, -2% when reported in CHF, to CHF 30.4 billion due to strong demand”
  • Core operating profit: “Core operating profit was +10% at CER (-1% in CHF) to CHF 11.9 billion, driven by higher sales and other revenue.”
  • IFRS operating profit: “IFRS operating profit was -6% in CHF to CHF 9.7 billion. IFRS diluted earnings per share were -8% in CHF.”
  • Core EPS, diluted: “Core EPS – diluted (CHF) 10.85 11.08 9 -2 IFRS operating profit 9,671 10,330 6 -6”
  • IFRS diluted EPS: “Net income attributable to Roche shareholders 6,871 7,410 –7 +5 22.6 23.9 Diluted EPS (CHF) 8.52 9.23 –8 +5”
  • IFRS net income: “Net income 7,325 7,832 –6 +6 24.1 25.3 Net income attributable to Roche shareholders 6,871 7,410”
  • Free cash flow: “Free cash flow 4,197 3,319 +26 +58 13.8 10.7 30 June 2026 31 December 2025”
  • Operating free cash flow: “Operating free cash flow 6,264 6,114 +2 +21 20.6 19.8 Free cash flow 4,197 3,319”
  • Pharmaceuticals Division: “Pharmaceuticals Division | 23,629 | 23,985 | 100.0 | 100.0 | 6 | -1”
  • Diagnostics Division: “Diagnostics Division | 6,735 | 6,959 | 100.0 | 100.0 | 3 | -3”
  • Ocrevus: “Ocrevus 3,470 7 2,300 2 758 10 - - 412 30 Multiple sclerosis”
  • Hemlibra: “Hemlibra 2,492 11 1,313 9 502 4 171 9 506 26 Haemophilia A”
  • Vabysmo: “Vabysmo 2,059 8 1,333 1 386 5 75 26 265 65 Eye diseases (nAMD, DME, RVO)”
  • Xolair: “Xolair3 1,673 27 1,673 27 - - - - - - Chronic hives, food allergies”
  • Phesgo: “Phesgo 1,318 18 318 0 425 9 88 15 487 47 Breast cancer”
  • Pathology Lab (Diagnostics): “Pathology Lab 874 852 13.0 12.2 11 3 Regions Europe, Middle East, Africa”

Copied from the press release ↗ and other documents in the company's results page ↗. A figure is published only if its sentence is in those documents.

Key takeaways

  1. Five FDA Priority Reviews build a late-2026 catalyst calendar

    Giredestrant, Enspryng in thyroid eye disease, Tecentriq in colon cancer and Gazyva in two kidney diseases got Priority Review. Giredestrant's PDUFA date is 30 November 2026.

  2. Divarasib beat approved KRAS G12C drugs head-to-head

    The phase III Krascendo 1 trial showed superiority in progression-free survival versus approved KRAS G12C inhibitors, with overall survival significance at interim. Roche positions it as best-in-class in lung cancer.

  3. Axelios 1 pushes Roche into next-generation sequencing

    The SBX-based platform enables same-day whole-genome sequencing in research workflows. Roche says it suits labs of all sizes and may reach clinical settings later.

  4. Subcutaneous Ocrevus and Phesgo conversion drive neurology and breast cancer

    About 44,000 patients are on Ocrevus SC globally, with about 60% of US SC volume from community practices. Phesgo's global conversion rate from Perjeta is 54%.

  5. Xolair biosimilar entry looms over the top growth driver

    Xolair's US sales grew on food allergy and chronic hives, with over 130,000 food allergy patients treated since launch. Roche expects the first biosimilar in the second half of 2026.

Questions

What were Roche's main regulatory wins in the first half of 2026?

The FDA granted five Priority Reviews: giredestrant in early-stage breast cancer, Enspryng in thyroid eye disease, Tecentriq in colon cancer, and Gazyva in primary membranous nephropathy and idiopathic nephrotic syndrome. The FDA also accepted filings for Lunsumio plus Polivy and Gazyva in lupus.

What is Roche doing in diagnostics?

Roche launched the Axelios 1 sequencing platform and won CE marks for Elecsys pTau217 and Elecsys IGRA TB. It also agreed to acquire PathAI to expand AI-driven digital pathology.

Which Roche medicines are driving growth?

Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo were the top growth drivers. Xolair grew on food allergy and chronic hives, and Hemlibra on adoption in non-inhibitor patients.

What business development did Roche announce?

Roche signed a global co-development and co-commercialisation deal with Nurix Therapeutics for the BTK degrader bexobrutideg, with a USD 700 million upfront payment. It also agreed to acquire PathAI for about USD 750 million in cash, with up to USD 300 million more contingent.

What competitive pressures does Roche face?

Biosimilars are eroding Actemra/RoActemra, Avastin and Herceptin, and a Xolair biosimilar is expected in the US in the second half of 2026. Tecentriq faces competitive pressure in Europe and Japan, and Vabysmo faces a competitive pricing environment.